ArticleBMC ophthalmology2025
AmblyoPlay-based multimodal visual therapy in pediatric anisometropic amblyopia: a pilot study of visual, oculomotor and sensorimotor outcomes.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis pilot exploratory study aimed to assess the impact of a 6-month app-based multimodal visual therapy program (AmblyoPlay®) on visual acuity (VA), stereopsis, oculomotor control, motor proficiency, and postural stability in children with anisometropic amblyopia.
methodsThis study, non-randomized controlled study included 29 children aged 7–13 years. Group I (n = 14) had anisometropic amblyopia and performed daily 20-minute gamified dichoptic therapy using AmblyoPlay® for 6 months. Group II (n = 15) were age- and sex-matched typically developing controls without intervention. Assessments included VA (LogMAR), stereopsis (Titmus Fly), oculomotor parameters (saccadic latency, smooth pursuit gain, optokinetic gain), motor proficiency (BOT-2 subtests), and postural stability (Sensory Organization Test). Group I was evaluated at baseline, 1, 3, and 6 months; controls at baseline and 6 months. Friedman and Wilcoxon signed-rank tests were used for within-group comparisons; Mann–Whitney U tests for between-group differences.
resultsIn Group I, amblyopic eye LogMAR VA improved from 0.23 ± 0.10 to 0.08 ± 0.05 at 6 months (p < 0.001), and stereopsis improved from 494.3 ± 874.5 to 60.7 ± 28.9 arcsec (p < 0.001). Significant reductions in saccadic latency and increases in smooth pursuit and optokinetic gains were observed (all p < 0.05). Motor proficiency and postural stability composite scores also improved significantly (p < 0.05). No significant changes occurred in controls.
conclusionsAmblyoPlay-based multimodal visual therapy led to significant improvements in visual and oculomotor function, with secondary benefits in motor coordination and balance, in pediatric anisometropic amblyopia.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.